1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. ZYDUS LIFESCIENCES LTD.
Zydus Lifesciences Ltd.
NSE: ZYDUSLIFE | BSE: 532321

Zydus Lifesciences Live Share Price Today, Share Analysis and Chart

Turnaround Potential
BasketIn 3 Starfolio Baskets
aboutZydus Lifesciences Ltd. is a global pharmaceutical company focused on the discovery, development, manufacturing, and marketing of a broad range of healthcare therapies. The company maintains a strong presence in the generic, branded, and consumer wel... Read More
US FDA InspectionsANDA Approvals
Ask AI about Zydus Lifesciences
1189.90-16.10(-1.33%)

42.42% Gain from 52W Low

834.2K
NSE+BSE Volume

NSE 13 Nov, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Durability score
00 / 100
Valuation Score
00 / 100
Momentum Score
00 / 100
Analyst Price Target
000

12

S

14

W

2

O

2

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

13Positive10Negative

Pass in checklist56.5%

045
55
100

PE Valuation Check

Right Now
Overvalued
-22.4%
1 Year Forward
Overvalued
-25.9%
INSIGHTZydus Lifesciences is overvalued at both current PE and future earnings estimates.

Zydus Lifesciences Stock Price Analysis

Day Price Range

-1.3% 1 Day return
1189.9 (LTP)
1,183.21,213
LowHigh

Week Price Range

-0.7% 1 Week return
1189.9 (LTP)
1,183.21,232.3
LowHigh

Month Price Range

5.1% 1 Month return
1189.9 (LTP)
1,093.51,266.6
LowHigh

52 Week Price Range

26.0% 1 Year return
1189.9 (LTP)
835.51,266.6
LowHigh
View full Price History/Seasonality

Zydus Lifesciences Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Hit

Zydus Lifesciences's Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

CURRENT EPS
50.1
AVG. ESTIMATE
39.6
LOW ESTIMATE
34.1
HIGH ESTIMATE
48.2
CURRENT EPS
AVG. ESTIMATE
Miss

EPS is expected to reduce by 20.9% in FY27

Consensus Recommendation

29 ANALYST Recommendations
HOLD

The consensus recommendation from 29 analysts for Zydus Lifesciences is HOLD

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Zydus Lifesciences Technical Analysis

Zydus Lifesciences EMA & SMA

Bullish+2
5 bullish, 3 bearish
Bullish5
Bearish3
5 Day1199.7
10 Day1198.3
12 Day1196.3
20 Day1187.5
26 Day1181.9
50 Day1165.8
100 Day1134.3
200 Day1082.4

Zydus Lifesciences Delivery And Volume

Daily Avg. Delivery Volume %
13 Nov, 202654.4%
Week59.4%
Month49.3%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Zydus Lifesciences Resistance and Support

1195.37
Pivot
First Resistance1207.5
Second Resistance1225.2
Third Resistance1237.3
First Support1177.7
Second Support1165.6
Third Support1147.9
Day RSI52.3
Day MACD14.4
Day MFI45.4
Day MACD Signal Line15

Zydus Lifesciences Beta

1 Month0.2
1 Year0.6
3 Month0.4
3 Year0.7

Zydus Lifesciences Price Change Analysis

↑5.1%
Over 1 Month
LowHigh
1093.51266.6
↑1.9%
Over 3 Months
LowHigh
10861266.6
↑26.7%
Over 6 Months
LowHigh
961.11266.6
↑26.0%
Over 1 Year
LowHigh
835.51266.6
All Technicals →

Zydus Lifesciences Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Zydus Family Trust (Pankaj R. Patel, Pritiben P. Patel And Sharvil P. Patel-Trustees)Promoter747,963,80175.0 %
Life Insurance Corporation Of IndiaDii37,591,9843.8 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Zydus Lifesciences Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
UBS PRINCIPAL CAPITAL ASIA LIMITEDBulkSell30 Aug 20241128.116,701,664NSE
INTEGRATED CORE STRATEGIES (ASIA) PTE.LTD.BulkPurchase28 May 2019258.215,460,159NSE
BLACKROCK FUNDS INTERNATIONAL OPPORTUNITIES PORTFBulkSell30 Nov 2015402.79555,000NSE
BLACKROCK FUNDS INTERNATIONAL OPPORTUNITIES PORTFBulkPurchase30 Nov 20154037,102,797NSE
BARING INDIA PRIVATE EQUITY FUND III LISTED INVESTMENTS LTDBlockSell27 Oct 2015427.754,604,326NSE
BARCLAYS MERCHANT BANK (SINGAPORE) LTDBlockPurchase27 Oct 2015427.754,604,326NSE
BARING INDIA PRIVATE EQUITY FUND III LISTED INVESTMENTS LTDBlockSell20 Oct 2015435.502,169,720NSE
BARCLAYS MERCHANT BANK (SINGAPORE) LTDBlockPurchase20 Oct 2015435.502,169,720NSE
BARING INDIA PRIVATE EQUITY FUND III LISTED INVESTMENTS LTDBlockSell14 Oct 20154241,559,839NSE
BARCLAYS MERCHANT BANK (SINGAPORE) LTDBlockPurchase14 Oct 20154241,559,839NSE
All deals
All insider trades

Zydus Lifesciences Corporate Actions

Zydus Lifesciences Dividend history and yield

Zydus Lifesciences dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Zydus Lifesciences dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
124 Jul 2026
1FINAL24 Jul 2026Equity Share
225 Jul 2025
11FINAL25 Jul 2025Equity Share
326 Jul 2024
3FINAL26 Jul 2024Equity Share
428 Jul 2023
6FINAL28 Jul 2023Equity Share
528 Jul 2022
2.5FINAL29 Jul 2022Equity Share

Zydus Lifesciences Bonus shares

Zydus Lifesciences bonus history along with announcement, record, ex-bonus dates, and bonus ratios.

#Ex-Date
Bonus RatioRecord Date
105 Apr 2010
1:206 Apr 2010
230 Aug 2006
1:131 Aug 2006

Zydus Lifesciences Board Meetings

Zydus Lifesciences past and upcoming board meetings.

#Ex-Date
PurposeNotes
104 Nov 2026
Quarterly Results-
211 Aug 2026
Quarterly Results-
319 May 2026
Audited Results, Dividend & Buy Back-
409 Feb 2026
Quarterly Results-
506 Nov 2025
Quarterly Results & Fund raisingInter-alia, to consider 1. Proposal for raising funds up to Rs. 5,000 Crores through the issuance of eligible securities of the Company by way of qualified institutions placement(s), rights issue or any other method...

Zydus Lifesciences Stock Split

Zydus Lifesciences stock split details, including announcement, record, and ex-split dates, along with the split ratios

#Ex-Date
Old FVNew FVRecord Date
106 Oct 2015
51-
All Corporate Actions

Zydus Lifesciences Research Reports

Zydus Lifesciences research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
111 Aug 2026Deven Choksey
Target
12551191Hold5.37%-0.09%pdf
210 Aug 2026Motilal Oswal
Target
11251191Neutral-5.54%-0.09%pdf
314 Jul 2026Deven Choksey
Target
12011156.9Accumulate3.81%2.85%pdf
424 May 2026Deven Choksey
Reco
Target
11351038.95Accumulate9.24%14.53%pdf
519 May 2026Motilal Oswal
Target
10801040.85Neutral3.76%14.32%pdf
All Reports of Zydus

Zydus Lifesciences Corporate Filings

Zydus Lifesciences BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
14 Nov 2026
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release
PDF
12 Nov 2026
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Updates on Joint Venture
Completion of transaction
PDF
07 Nov 2026
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of the post results earnings call held on November 4, 2026.
PDF
06 Nov 2026
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release
PDF
06 Nov 2026
Zydus Lifesciences Ltd - 532321 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India
PDF
VIEW ALL

Zydus Lifesciences Documents

Zydus Lifesciences Earnings Call

Zydus Lifesciences earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
07 Nov 2026Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptPdf
04 Nov 2026Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomePdf
18 Aug 2026Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptPdf
24 May 2026Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptPdf
15 Feb 2026Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptPdf
view all

Zydus Lifesciences Annual Reports

Zydus Lifesciences financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Pdf
2025Annual Report Mar-2025Pdf
2024Annual Report Mar-2024Pdf
2023Annual Report Mar-2023Pdf
2022Annual Report Mar-2022Pdf

Zydus Lifesciences Credit Ratings

Zydus Lifesciences credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
02 Aug 2026india ratingsIndia Ratings Maintains Cadila Pharmaceuticals’s Bank Loan Facilities in Non-Cooperating Category and Withdraws RatingLink
04 Feb 2026india ratingsIndia Ratings Downgrades Cadila Pharmaceuticals’s Bank Loan Facilities to ‘IND BBB’/Negative and Migrates Rating to Non-Cooperating CategoryLink
29 May 2025india ratingsIndia Ratings Downgrades Cadila Pharmaceuticals’ Bank Facilities to ‘IND A-’/Negative; Rates Additional Limits Link
19 Jan 2022crisil ratingsCadila Healthcare LimitedCadila Healthcare Limited:Ratings ReaffirmedLink
29 Nov 2021crisil ratingsCadila Healthcare LimitedCadila Healthcare Limited:Rating outlook revised to 'Positive'; Ratings reaffirmedLink

Zydus Lifesciences Investor Presentations

Zydus Lifesciences investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
04 Nov 2026Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor PresentationPdf
23 Aug 2026Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor PresentationPdf
11 Aug 2026Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor PresentationPdf
19 May 2026Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor PresentationPdf
09 Feb 2026Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor PresentationPdf

Zydus Lifesciences - Company Profile

Zydus Lifesciences Management Structure

Zydus Lifesciences management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Dr. Mukul JainExecutive(Biology)-Mar 26
Mr. Vijay BhaleraoWhole Time Director(Subsidiary Company)-Mar 26
Mr. Pravin IyerExecutive(Medicinal Chemistry)-Mar 26
Mr. Alok GargExecutive(Business Strategy.,International Markets,Strategy)-Mar 26
Mr. Girishankar GopalakrishnanBusiness Executive(MedTech)-Mar 26
Mr. Gaurav SuchakExecutive(Supply,Information Technology)-Mar 26
Mr. Keyur ParekhExecutive(Business Strategy.)-Mar 26
Mr. Vikram ShuklaExecutive(Operations)-Mar 26
Mr. Sanjeev KumarExecutive(Biologics,Research,Manufacturing)-Mar 26
Mr. Kapil MaithalExecutive(Vaccines,Manufacturing,Operations)-Mar 26
Dhaval N SoniCompany Secretary,Compliance Officer-Mar 26
Mr. M E KannanExecutive(Pharmaceuticals,Technology)-Mar 26
Mr. Rishikesh RavalExecutive(Human Resources,Corporate Communication.)-Mar 26
Dr. Amrut NaikExecutive(International Markets)-Mar 26
Ms. Swati DalalExecutive(Formulations,Business.)-Mar 26
Mr. Vipul DoshiExecutive(Quality,Regulatory Affairs)-Mar 26
Mr. Prashant SharmaTechnical.(Formulations,API.)-Mar 26
Mr. Harish SadanaPresident(Corporate)-Mar 26
Mr. Tushar D. ShroffChief Financial Officer-Mar 26

Zydus Lifesciences Board of Directors

Zydus Lifesciences Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Sharvil P PatelExecutive Director & MD4500Mar 26
Ganesh N NayakExecutive Director460Mar 26
Akhil A. MonappaIndependent Non Exe. Director45Mar 26
Bhadresh K ShahIndependent Non Exe. Director41Mar 26
Shelina P. ParikhIndependent Non Exe. Director41Mar 26
Mukesh PatelNon-Exec & Non-Independent Dir40Mar 26
Upsana KamineniIndependent Non Exe. Director35Mar 26
Pankaj R PatelChairman(Non Exe)&Dir(Non-Ind)9Mar 26
Kulin S LalbhaiIndependent Director-Mar 26
Dhaval N SoniCompany Sec. & Compli. Officer-Mar 26

Zydus Lifesciences Brands

Brands owned by Zydus Lifesciences

LOGOBRAND NAME
Haem Up Gems
Lorfast Meltab
Fludac
Ocid QRS
LOGOBRAND NAME
Cadisper C
Thycad
Add App
MITOCIN
LOGOBRAND NAME
Narebox
Rabeloc
Halonix Inj
Vasograin
LOGOBRAND NAME
Campicilin
Depin
Envas
Ocid
Website: www.zyduscadila.com

About the company - Business Profile

Zydus Lifesciences Ltd. is a global pharmaceutical company focused on the discovery, development, manufacturing, and marketing of a broad range of healthcare therapies. The company maintains a strong presence in the generic, branded, and consumer wellness segments across various therapeutic areas, including oncology, cardiology, and gastrointestinal health. As a vertically integrated entity, Zydus manages its operations from Active Pharmaceutical Ingredients (APIs) to finished formulations, supported by extensive research and development capabilities.

Key Points

  • Key Facts: Founded in 1952 and headquartered in Ahmedabad, India, Zydus Lifesciences is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). It operates as a leading player in the global generics market, particularly in the United States and India.
  • Operations and Resources: The company operates 41 manufacturing facilities globally, including sites in India, France, the UK, Brazil, and Myanmar. Its infrastructure includes 16 USFDA-inspected facilities, 6 API sites, and 7 R&D centers dedicated to NCEs, generics, vaccines, and biosimilars.
  • Ownership and Significance: Zydus is a promoter-led company (Patel family). It ranks as the 5th largest generic company in the US by prescriptions and holds a leadership position in several chronic therapeutic segments in India.
  • Sustainability and Innovation: In FY25, Zydus invested INR 18,521 million (8% of revenue) in R&D. It has received a "Strong" ESG rating with a score of 66/100 and ranks among the top 3 in the Global Drug & Pharmaceutical Sector by S&P Global ESG scores.

Business Model and Segment Performance Zydus operates through a diversified model targeting high-growth therapeutic areas and complex generics. The company’s revenue is balanced between branded formulations (India and Emerging Markets), US generics, and consumer wellness.

Financial Performance (FY2024-25):

  • Total Revenue: INR 2,32,415 million (FY25), representing a significant growth from INR 1,95,474 million in FY24.
  • EBITDA: INR 70,585 million with an EBITDA margin of 30.4% in FY25.
  • Net Profit: Reported Net Profit of INR 46,726 million in FY25.

Revenue Breakdown (FY2025):

  • India Formulations: INR 59,281 million (9.9% YoY growth).
  • US Formulations: US$ 1.2 billion (approximate).
  • Consumer Wellness: Primarily driven by brands like Sugar Free, Complan, and Everyuth through its subsidiary Zydus Wellness.

Key Products and Technology Advancements:

  • Innovation Products: Bilypsa (Saroglitazar) for MASH/NAFLD and Oxemia (Desidustat) for anemia associated with Chronic Kidney Disease.
  • Biosimilars: Portfolio of 14 launched products in India, including 4 Antibody-Drug Conjugates (ADCs).
  • Complex Generics: Focus on difficult-to-make formulations like transdermals and injectables.

Strategic Initiatives and Partnerships:

  • Acquisitions: Signed definitive agreements to acquire Agenus' US facilities to expand advanced biologics manufacturing capabilities in California.
  • US Market Strategy: Focusing on a "One-Stop Solution" from pre-clinical to commercial manufacturing to capitalize on the domestication wave in the US pharmaceutical industry.
  • Workforce: Employs 27,000+ personnel globally, including a dedicated team of over 1,500 scientists.

References

  1. Annual Report May 2025
  2. Investor Presentation Nov 2025
  3. Investor Presentation Feb 2026
  4. Annual Report May 2024

Zydus Lifesciences FAQ

Zydus Lifesciences today is trading in the red, down by 1.33% at ₹1,189.9.
Zydus Lifesciences is currently trading down 1.33% on an intraday basis. In the past week the stock fell 0.67%. Stock has been up 1.94% in the past quarter and rose 26.03% in the past year. You can view this in the share price history/seasonality section.
Zydus Lifesciences is listed on NSE with the ticker ZYDUSLIFE and on BSE as 532321. It's currently trading on NSE at a share price of ₹1,189.9 and on BSE with a share price of ₹1,191.
The market cap of Zydus Lifesciences is ₹119,731.78 Cr. as of Nov 13, 2026.
Zydus Lifesciences announced a FINAL dividend of 100% which equals ₹1 in Jul 24, 2026.The last three ex-dates for Zydus Lifesciences were Jul 25, 2025, Jul 26, 2024 and Jul 28, 2023. To view the full dividend history of Zydus Lifesciences click here.
Zydus Lifesciences has undergone 1 stock split and announced bonus shares 2 times since its BSE/NSE listing. The latest announcement for Zydus Lifesciences stock split was on Oct 06, 2015 at a ratio of 5:1 and the last bonus share announcement was on Apr 05, 2010 at a ratio of 1:2.
Zydus Lifesciences reported ₹8,039.5 Cr. in revenue, ₹927.7 Cr. in net profit, and ₹2,025.7 Cr. in EBITD as of Nov 04, 2026 for Q2 FY26-27.
According to the predictions of 29 analysts, the share price prediction for Zydus Lifesciences is ₹1,233.12 with an upside of 4%.
The PE ratio of Zydus Lifesciences is 28.63 as of Nov 13, 2026.
The PB ratio of Zydus Lifesciences is 4.27 as of Nov 13, 2026.
You can view the latest analyst reports on the Zydus Lifesciences reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×